Cancer remains one of the developed world’s most serious health problems despite recent advances. Beyond traditional chemotherapeutic approaches to treating cancer, one of the newer interventions is to selectively restrict the blood supply that feeds solid tumors.
Regeneron's approach in oncology is focused on anti-angiogenesis.
The growth of solid tumors requires the development of new blood vessels, a process called angiogenesis, to sustain the cancer by providing oxygen and nutrients. Regeneron's approach in oncology is focused on anti-angiogenesis - disrupting the flow of blood to tumors by binding particular proteins that stimulate the formation of new blood vessels.
We have several clinical-stage drug candidates in the pipeline that have been developed based on our understanding of angiogenesis.
Enoticumab (REGN421) is a fully human monoclonal antibody that binds the protein delta-like ligand factor 4 (Dll4).
Nesvacumab (REGN910) is a fully human monoclonal antibody that binds angiopoietin-2 (Ang2), a novel angiogenesis target for inhibiting tumor growth. Regeneron is developing nesvacumab (REGN910) as part of our antibody collaboration with Sanofi.
Click here for more information about our antibody collaboration with Sanofi.
REGN1979 is a bi-specific antibody that simultaneously targets CD20 and CD3 receptors on T-cells. Our bi-specific antibodies are developed using our VelociSuite technologies to target tumor antigens and T-cells receptors in order to harness the oncolytic properties of T-cells.
This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.